CoChat

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial

Open access
Meissner, Eric G., McLaughlin, Mary, Matthews, Lindsay, Gharib, Ahmed M., Wood, Bradford J., Levy, Elliot, Sinkus, Ralph, Virtaneva, Kimmo, Sturdevant, Dan, Martens, Craig, Porcella, Stephen F., Goodman, Zachary D., Kanwar, Bittoo, Myers, Robert P., Subramanian, Mani, Hadigan, Colleen, Masur, Henry, Kleiner, David E., Heller, Theo, Kottilil, Shyam, Kovacs, Joseph A., Morse, Caryn G. · 2016 · Liver International
Cited by 94

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: Chronic liver injury can result in fibrosis that may progress over years to end‐stage liver disease. The most effective anti‐fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed. Aim: The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase‐like 2 (LOXL 2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV‐HIV co‐infection and advanced liver disease. Methods: Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg intravenously every 2 weeks for 22 weeks. Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis. Results: Treatment was well‐tolerated with no discontinuations due to adverse events. No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment. Exploratory transcriptional and protein profiling using paired pre‐ and post‐treatment liver biopsy and serum samples suggested up‐regulation of TGF‐β3 and IL‐10 pathways with treatment. Conclusion: In this open‐label, pilot clinical trial, simtuzumab treatment was well‐tolerated in HCV‐ and HIV‐infected subjects with advanced liver disease. Putative modulation of TGF‐β3 and IL‐10 pathways during simtuzumab treatment merits investigation in future trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13177

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 94

Metadata

Authors
Meissner, E. G., McLaughlin, M., Matthews, L., Gharib, A. M., Wood, B. J., Levy, E., Sinkus, R., Virtaneva, K., Sturdevant, D., Martens, C., Porcella, S. F., Goodman, Z. D., Kanwar, B., Myers, R. P., Subramanian, M., Hadigan, C., Masur, H., Kleiner, D. E., Heller, T., Kottilil, S., Kovacs, J. A., & Morse, C. G.
Venue
Liver International
Publisher
Wiley
Published
2016-07-06
Volume
36
Issue
12
Pages
1783-1792
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2408729117
Cited by
94
References
7
FWCI
7.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial. https://app.cochat.ai/papers/10.1111/liv.13177
The paper
Meissner, E. G., McLaughlin, M., Matthews, L., Gharib, A. M., Wood, B. J., Levy, E., Sinkus, R., Virtaneva, K., Sturdevant, D., Martens, C., Porcella, S. F., Goodman, Z. D., Kanwar, B., Myers, R. P., Subramanian, M., Hadigan, C., Masur, H., Kleiner, D. E., Heller, T., . . . Morse, C. G. (2016). Simtuzumab treatment of advanced liver fibrosis in HIV and HCV‐infected adults: results of a 6‐month open‐label safety trial. Liver International. https://doi.org/10.1111/liv.13177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.